Roche gets USFDA clearance for Elecsys pTau181 test for Alzheimer's disease

Developed in collaboration with Eli Lilly and Company, this minimally invasive test provides clinicians with information that can help identify patients in early stages of cognitive decline who are unlikely to have Alzheimer's-related amyloid pathology. The result should be interpreted in conjunction with other clinical information.

"By bringing Alzheimer's blood-based biomarker testing into primary care, we can help patients and their clinicians get answers sooner to support them earlier in their journeys," said Brad Moore, President and CEO of Roche Diagnostics North America. "This milestone reflects Roche's leadership in diagnostics and our commitment to expanding access to innovative testing for patients and their clinicians."

Alzheimer's is complex, with multiple pathologies impacting more than 7 million Americans. Unfortunately, 92% of patients with mild cognitive impairment (early-stage symptomatic disease) go undiagnosed and are therefore unable to explore whether therapeutic intervention is possible.

"Until now, Alzheimer's biomarker testing has largely been limited to specialty settings, such as neurology. By enabling use in primary care, the Elecsys pTau181 test has the potential to significantly broaden patient access to minimally invasive testing and helps preserve specialist resources. Primary care clinicians can better guide appropriate referrals so neurologists can focus on the patients most likely to need advanced evaluation and treatment," the release stated.

With more than 4,500 Roche instruments already installed in clinical laboratories across the United States, health systems and providers are well positioned to rapidly integrate the Elecsys pTau181 test into their existing infrastructure. 

Elecsys pTau181 is an FDA-cleared, blood-based Alzheimer's test indicated as an aid in the initial assessment for Alzheimer's and other causes of cognitive decline in the primary-care setting. The performance was evaluated in a multicenter, non-interventional clinical study in 312 participants. Results demonstrated that in an early disease-stage, low-prevalence population reflective of primary-care setting, Elecsys pTau181 could rule out Alzheimer's pathology with a 97.9% negative predictive value (NPV). Fully automated on Roche's installed base of instruments, Elecsys pTau181 allows laboratories to integrate testing quickly and at scale – creating new opportunities to broaden access and reduce delays for patients and their providers.

With FDA clearance, the Elecsys pTau181 test may provide information that can help healthcare providers and systems:

• Enable early-disease-stage assessment of patients with cognitive complaints by providing information that may help aiding clinicians in ruling out Alzheimer's-related amyloid pathology
• Better integrate primary care into the Alzheimer's diagnosis pathway and expand testing availability
• Improve referral quality by guiding physicians' decisions on patient referrals
• Help preserve neurologists' resources for patients with the greatest need
• The clearance of Elecsys pTau181 is an important milestone in Roche's ongoing work to transform Alzheimer's diagnostics. Looking ahead, Roche is advancing a comprehensive portfolio that has the potential to further shape diagnostic pathways and support earlier, more accurate detection of neurological diseases. This work reflects Roche's commitment to lead with science in developing transformational solutions that both improve patient outcomes and simplify laboratory operations.

In addition to FDA clearance in the United States, Roche recently received CE Mark certification in Europe for the Elecsys pTau181 test.